Upon the analysis presented in this article, I rate Medpace Holdings (NASDAQ: MEDP ) with a buy rating. The company has achieved excellent financial results with a 123.65% increase in its revenues between 2020 and 2024Q3. In addition, it has an impressiveDaniel Mellado is an economist from Carabobo University with a Master's Degree in Statistics from Simon Bolivar University, both obtained in Venezuela.Daniel worked analyzing the agricultural commodity market and the financial investment portfolio for an ag ...

Group 1 - Medpace Holdings, Inc. is currently under investigation for securities fraud, which raises concerns among investors [1] - Affected investors are encouraged to contact the Schall Law Firm for potential legal action [1]

Core Viewpoint - The Schall Law Firm is inviting shareholders who have incurred losses to participate in an inquiry regarding potential securities law violations by Medpace Holdings, Inc. [1] Group 1 - The inquiry is focused on possible violations of securities laws that may have affected shareholders [1] - Shareholders are encouraged to join the investigation if they have experienced financial losses related to Medpace Holdings, Inc. [1] - The law firm aims to determine whether the company engaged in any unlawful practices that could have impacted its stock performance [1]

Analyst Estimates and Stock Performance - Positive estimate revisions for Medpace indicate optimism about the company's business outlook [1] - Empirical research shows a direct correlation between estimate revisions and impending stock price performance [2] - Medpace currently holds a Zacks Rank of 2 (Buy), with stocks at 1 delivering an average annual return of +25% since 1988 [3] - The consensus EPS projection for Medpace has increased by 0.81% in the past 30 days [3] Valuation Metrics - Medpace trades at a PEG ratio of 1.8, higher than the industry average of 1.41 [4] - The company's Forward P/E ratio is 28.25, representing a premium compared to the industry average of 17.02 [8] Industry and Sector Performance - The Medical Services industry, part of the Medical sector, has a Zacks Industry Rank of 154, placing it in the bottom 39% of over 250 industries [4] - The top 50% rated industries outperform the bottom half by a factor of 2 to 1 [5] Recent Stock Performance - Medpace's stock closed at $352.01, marking a +0.32% move from the prior day, outperforming the S&P 500's daily gain of 0.16% [6] - Over the past month, Medpace shares gained 1.43%, while the Medical sector lost 5.3% and the S&P 500 lost 2.2% [6] Upcoming Earnings Release - Medpace plans to announce its earnings on February 10, 2025, with projected earnings of $2.97 per share, representing year-over-year growth of 20.73% [7] - The latest consensus estimate predicts revenue of $536.37 million, indicating a 7.62% increase compared to the same quarter of the previous year [7]

The latest trading session saw Medpace (MEDP) ending at $346.81, denoting a +1.39% adjustment from its last day's close. This move outpaced the S&P 500's daily loss of 1.11%. On the other hand, the Dow registered a loss of 0.42%, and the technology-centric Nasdaq decreased by 1.89%.The provider of outsourced clinical development services's stock has dropped by 2.88% in the past month, exceeding the Medical sector's loss of 6.22% and lagging the S&P 500's loss of 1.7%.Market participants will be closely foll ...

Investors interested in Medical stocks should always be looking to find the best-performing companies in the group. Is Medpace (MEDP) one of those stocks right now? Let's take a closer look at the stock's year-to-date performance to find out.Medpace is one of 1020 companies in the Medical group. The Medical group currently sits at #2 within the Zacks Sector Rank. The Zacks Sector Rank considers 16 different groups, measuring the average Zacks Rank of the individual stocks within the sector to gauge the stre ...

In the latest trading session, Medpace (MEDP) closed at $339.05, marking a +0.52% move from the previous day. The stock trailed the S&P 500, which registered a daily gain of 0.73%. Meanwhile, the Dow gained 0.16%, and the Nasdaq, a tech-heavy index, added 0.98%.Coming into today, shares of the provider of outsourced clinical development services had lost 0.14% in the past month. In that same time, the Medical sector lost 3.8%, while the S&P 500 gained 0.34%.The investment community will be closely monitorin ...

RADNOR, Pa., Nov. 06, 2024 (GLOBE NEWSWIRE) -- The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) is currently investigating potential violations of the federal securities laws on behalf of investors of Medpace Holdings, Inc. (NASDAQ: MEDP) (“Medpace”). On October 21, 2024, during after-market hours, Medpace reported its third quarter 2024 financial results and cut its revenue guidance for full-year 2024. During an investor call held on October 22, 2024, Medpace indicated that the company had ...

Medpace (NASDAQ: MEDP ) is a rapidly-growing clinical research organization, providing full-service Phase I-IV clinical development services to the biotechnology, pharmaceutical and medical device industries. The current CEO, August Troendle, founded the company after gaining extensive experience of the difficulties faced by emerging biotech companies in a 22-year-old self-taught investor, who is currently aiming for his Master of Science in Business Administration with focus on finance and accounting, mean ...

RADNOR, Pa., Oct. 30, 2024 /PRNewswire/ -- The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) is currently investigating potential violations of the federal securities laws on behalf of investors of Medpace Holdings, Inc. (NASDAQ: MEDP) ("Medpace"). On October 21, 2024, during after-market hours, Medpace reported its third quarter 2024 financial results and cut its revenue guidance for full-year 2024. During an investor call held on October 22, 2024, Medpace indicated that the company had see ...